Qiagen (QGEN) is attracting interest from multiple private equity firms, including KKR (KKR), EQT, Advent, TPG (TPG), and Bain Capital, with expectations that shareholders may demand at least $50/share, matching Thermo Fisher's (TMO) rejected offer from six years ago, Dietmar Palan of Manager Magazin reports. manager-magazin.de/unternehm… >Reference Link
1
127
Zeb retweeted
Albuquerque turned a wall of its airport bookshop over to its local university press, and goddamn, now I want this in every airport.
$LSTA buy-out w/ CVRs. No clue on the details, but they sound very do-able just from the PR: Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash. Additionally, Lisata stockholders will be entitled to receive two non-tradeable contingent value rights (CVRs), payable as follows: (1) $1.00 per share, in cash, within 12 months of the date on which rights to certepetide in the Greater China region revert to Lisata from Qilu Pharmaceutical; and (2) $1.00 per share, in cash, upon the filing of an NDA or similar registration document by Kuva for approval to commercialize certepetide in any indication in any jurisdiction.
1
393
Geez: @realDonaldTrumpDonald J. Trump
A very sad thing happened last night in Hollywood. Rob Reiner, a tortured and struggling, but once very talented movie director and comedy star, has passed away, together with his wife, Michele, reportedly due to the anger he caused others through his massive, unyielding, and incurable affliction with a mind crippling disease known as TRUMP DERANGEMENT SYNDROME, sometimes referred to as TDS. He was known to have driven people CRAZY by his raging obsession of President Donald J. Trump, with his obvious paranoia reaching new heights as the Trump Administration surpassed all goals and expectations of greatness, and with the Golden Age of America upon us, perhaps like never before. May Rob and Michele rest in peace!
1
330
UNITED STATES RATINGS CUT TO Aa1 FROM Aaa BY MOODY'S
poetryfoundation.org/poems/4…
2
285
$KROS Keros Therapeutics announced that the global development and commercialization license agreement with Takeda (TAK) to advance elritercept became effective on January 16, 2025
403



